BURLINGTON,TriPath Imaging says it has made significant advances in detection of cervical cancer and breast cancer.

The company says it has completed the selection of so-called molecular marker panels for the cervical and breast cancer products.

“We have crossed an important threshold in the product development process of our next-generation cancer diagnostics program, said Dr. Paul Sohmer, chairman, president and chief executive officer of TriPath Imaging, in a statement. “This is critical to our corporate mission to create solutions that redefine the early detection and clinical management of cancer.”

TriPath is seeking to develop and commercialize molecular diagnostic products for malignant melanoma and cancers of the cervix, prostate and ovary.

“The markers have met our initial clinical performance specifications, paving the way for us to complete assay optimization in the first half of 2004 and to initiate external research studies with leading academic centers in mid-2004,” Sohmer added.

TriPath Imaging: www.tripathimaging.com